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Objectives: Diabetes Mellitus is best managed through a combination of HbA1c 
testing, self-testing of blood glucose, and close interactions with HCPs. It has been 
previously shown that Italian diabetes patients have a very low rate of adherence 
to appropriate care, compared to those in other EU countries. In this study, we 
examined Italian diabetes patient preferences related to education and moni-
toring compared to patients in other EU5 countries. MethOds: A total of 3,013 
diabetes patients in the EU5 were sampled. Questions focused on demographic, 
lifestyle, treatment, access to information, and socioeconomic status. Data were 
compared across countries and reported behaviors compared to current patient 
treatment guidelines. Results: Despite guidelines stating that all patients must 
receive HbA1c testing twice per year, 42.5% of Italian patients reported receiving 
an HbA1c test in the past 12 months compared to 70.5% in other EU5 countries. 
Instead, these patients are favoring blood glucose self-monitoring, which has 
been previously shown to be an insufficient substitute for HbA1c testing. Italian 
patients also claimed that they do not want their doctor or nurse managing their 
diabetes more so than patients in any other tested country. Italians get diabetes 
information from Newspapers/Magazines, Internet, TV/Radio, Relatives/Friends 
more than other Europeans (37% v 34%; 33% v 28%; 30% v 26%; 25% v 21% respec-
tively). cOnclusiOns: While many Italian diabetes patients are reporting low 
adherence to guideline driven testing and preferences for managing their own 
diabetes without intervention from their HCP, change is needed. This represents a 
major opportunity for more targeted Italian patient management solutions built on 
Italian patient preferences and recognition of necessary change drivers to realize 
more cost-effective care. This study demonstrates how local patient preferences can 
impact outcomes, and therefore must be built into chronic disease management 
solutions for meaningful change to occur.
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Objectives: Type 1 diabetes is often associated with complications that may have 
a pronounced impact on health-related quality of life (HRQoL). The aim was to 
conduct a systematic literature review to identify studies conducted exclusively in 
type 1 diabetes populations reporting utility values for diabetes-related complica-
tions. MethOds: Literature searches of the PubMed, EMBASE and Cochrane Library 
databases were performed in line with PRISMA guidance; searches used Medical 
Subject Heading (MeSH) terms supplemented with free-text terms. For inclusion, 
studies were required to be conducted exclusively in adults with type 1 diabe-
tes, published in English from 2000 onwards, and report utility values determined 
using either direct or indirect assessment methods. Results: Searches identified 
a total of 20 studies reporting utility values for complications in type 1 diabetes, 
of which a total of 9 studies used the EQ-5D, 2 used the 15D, 3 used the Quality of 
Well-Being questionnaire and 5 used direct methods including time trade-off and 
standard gamble. For patients with no complications reported utility values ranged 
from 0.90–0.98. Complications including stroke (reported disutility range −0.105 to 
−0.291), neuropathy (range −0.055 to −0.358) and blindness (range −0.132 to −0.208) 
were associated with among the largest decrements in utility values. Poor glycemic 
control was also found to be associated with lower utility values. Data gaps in the 
literature exist, e.g. EQ-5D utility values for amputation and end-stage renal dis-
ease are lacking. cOnclusiOns: Differences between type 1 and type 2 diabetes 
populations mean for economic evaluation it is preferable to obtain utility values 
from exclusively type 1 diabetes populations. In type 1 diabetes the presence of 
complications has a significant detrimental impact on HRQoL, but the magnitude of 
the impact depends on the choice of HRQoL instrument. This will have implications 
on cost-effectiveness models of type 1 diabetes.
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Objectives: Diabetes mellitus (DM) is a chronic disease and patients have higher 
objective healthcare needs compared to the general population. The healthcare sup-
portive services help the good control of diabetes, avoiding or delaying the disease 
complications and assuring the patient’s adherence to the treatment. The objec-
tive of this study is to assess the patients reported needs of additional healthcare, 
psychological or family supportive care and the specific gaps in the healthcare 
management of the disease in Bulgaria. MethOds: A total of 245 adults diagnosed 
with DM type 1 and 2 were recruited and completed a self-report questionnaires at 
three hospitals - in the capital and in two main other cities. Of them 203 were com-
plete and eligible for analysis. Unmet needs were assessed using 15-item question-
naire. The data were examined using descriptive statistics. Results: Unmet needs 
were most commonly reported in the aspects of healthcare services’ domains. The 
three most frequently endorsed items of “moderate to severe” unmet needs were: 
additional information about the disease from the endocrinologist (65.35%), struc-
tured information about the disease and its treatment given in the hospital from 
the doctor (68.81%) and needs of special foot care medical offices for patients with 
diabetic neuropathy (68.81%). Approximately 76% of the patients reported having 
unmet needs of more free test-strips for self-monitoring blood glucose, medicinal 
products and special healthcare services for diabetics. 73 patients (36.14%) reported 
high importance of the active participation of the pharmacist in community phar-
macy in recognizing of probable and current drug related problems. 101 of the 
patients (50%) reported need of higher psychological support from their relatives 
18 had HbA1c> 8.0%. A total of 42% (126/302) used basal-insulin only, 29% (88/302) 
bolus-insulin only, 22% (66/302) basal-bolus, 5% (16/302) premixed and 2% (6/302) 
other combinations. Of all respondents, 81% (246/302) had previously experienced 
non-severe (self-managed) hypoglycaemia (79% (59/75) in those with HbA1c> 8%), 
with 11% (28/246) reporting 3 events per-week, 33% (80/246) once-a-week, and 29% 
(72/246) once-a-month. 30% (92/302) had previously experienced severe hypoglycae-
mia requiring help from others, with half (46/92) reporting 1-3 such events during 
past year. 73% (221/302) of respondents tested blood glucose 2-5 times-daily. Of 
192 respondents using basal insulin, 134 (70%) injected ≤ 1 time-a-day, whilst 30% 
(58/192) injected ≥ 2 times-daily. When asked about intensifying by adding bolus-
insulin or switching to premix, 58% (73/126) of basal-only patients would be hesitant. 
Most frequent reason for hesitation was increased number of daily injections (44%, 
32/73), as well as pain/discomfort of injections and risk of weight gain (both 23%; 
17/73), hypoglycaemia risk (22%; 16/73), difficulty calculating bolus dose with food 
(21%; 15/73). cOnclusiOns: Number and timing of injections, dose calculation, 
risk of hypoglycaemia and weight gain are barriers to insulin intensification among 
T2DM patients on basal insulin in Italy. Therapies addressing these may help to 
achieve treatment goals.
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Objectives: Diabetes mellitus is a serious health problem. Medication adherence 
is a key determinant of therapeutic success in patients with diabetes mellitus. 
The purpose of this study was to assess medication adherence and its potential 
association with diabetes related knowledge in patients with type 2 diabetes mel-
litus. MethOds: This study was carried out at the outpatient clinics of a public 
sector teaching hospital in Sargodha, Pakistan. Besides demographic and dis-
ease-related questions, previously validated questionnaires, Morisky Medication 
Adherence Scale and Michigan diabetes knowledge test was used to assess the 
medication adherence and diabetes related knowledge, respectively. Descriptive 
statistics were used to determine the demographic and disease characteristics 
of the patients while Spearman rank correlation was employed to measure the 
association between medication adherence and knowledge. Results: Three hun-
dred and ninety two patients were interviewed. Out of 392 patients, 245 (62.5%) 
of the patients had average knowledge about diabetes while 282 (71.9 %) were 
categorized as poor adherent. Only 13 patients (3.3 %) were considered as good 
adherent in the study. The correlation coefficient between total scores of knowl-
edge and total medication adherence score was 0.036 (p< 0.05), indicating a weak 
correlation between knowledge scores and adherence level. cOnclusiOns: 
Knowledge of diabetes mellitus among these patients was average; however, 
adherence to drug therapy was also poor. Patients’ knowledge about diabetes had 
positive association with medication adherence. Improving diabetes knowledge 
of people can result in better adherence, which may result in better control of 
diabetes.
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Objectives: Patient adherence with a therapeutic regimen predicts success-
ful treatment and reduces the severity of negative complications. The objective 
of this study was to explore the relationship between Health-Related Quality of 
Life (HRQoL) and treatment adherence among type 2 diabetes mellitus patients 
in Sargodha, Pakistan. MethOds: The study was designed as a cross-sectional 
descriptive survey. Type 2 diabetic patients attending a tertiary care institute in 
Sargodha, Pakistan were targeted for the study. The Urdu version of the Morisky 
Medication Adherence Scale (MMAS-Urdu) and EuroQol Quality of Life Scale (EQ-
5D) was used to assess medication adherence and HRQoL, respectively. Descriptive 
statistics were used for the elaboration of socio-demographic characteristics. The 
Spearman’s Rho correlation test was used to measure the association between 
medication adherence and HRQoL. P < 0.05 was taken as significant. Results: 
Three hundred and ninety two patients were approached for the study. The cohort 
was dominated by males (n= 222, 56.60 %) with 5.58± 4.09 years of history of type 2 
diabetes mellitus. The majority of respondents (n= 137, 34.90 %) was categorized in 
age group of 51 to 60 years with mean age of 50.77 ± 9.671 years. The present study 
highlighted that individuals with type 2 diabetes mellitus had decreased HRQoL 
(0.4715 ± 0.3360) and poor medication adherence (4.44± 1.8). Significant, yet weak 
positive correlations were observed between medication adherence and HRQoL (r= 
0.217 and 0.136 for EQ-5D and EQ-VAS respectively). cOnclusiOns: Although the 
association between adherence to therapeutic regimen and HRQoL in the present 
study cohort was significant, it was rated as weak, hence failed in producing an 
overall impression on quality of life. The study, therefore, highlights the need to 
identify other individual factors affecting HRQoL among type 2 diabetes mellitus 
patients in Pakistan.
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as fixed effects and baseline value as covariate. The model was chosen in accord-
ance with the pre-specified model for the clinical trial. Results: SF-36 estimated 
treatment differences (ETD; IDegLira–IGlar), at EOT were 1.9 points [95% CI: 0.8; 3.1] 
(p< 0.001) and –0.1 points [95% CI: –1.5; 1.3] (NS) for physical and mental component 
summary scores, respectively. Mean EQ-5D score ± SD at baseline was 0.901 ± 0.083. 
At EOT mean EQ-5D score ± SD was 0.915 ± 0.070 and 0.903 ± 0.084 for IDegLira and 
IGlar, respectively; ETD 0.017 points [95% CI: 0.007; 0.026] (p= 0.001). cOnclusiOns: 
This analysis suggests that IDegLira provides a statistically significant improvement 
in health utility compared with IGlar, in patients with T2D inadequately controlled 
on IGlar and metformin. The health utility improvement was generally driven by 
improvement in physical health, while mental health remained stable.
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Objectives: Data on wastage behaviours of patients with diabetes taking mealtime 
insulin (MTI) with a prefilled disposable pen or reusable pen with disposable car-
tridge are lacking. A patient survey was undertaken to estimate the average number 
of MTI units discarded per pen/cartridge by patients with diabetes taking > 20 units/
day, based on injection habits when insufficient insulin remains in a pen/cartridge 
to administer a full dose in a single injection. MethOds: Cross-sectional, online, 
self-reported survey of MTI usage and wastage behaviours in adults with type 1 or 
2 diabetes [T1D, T2D] using > 20 units/day of MTI administered via 100 units/mL 
pen/cartridge for ≥ 1 month, conducted between February and March 2015 in four 
EU countries [France, Germany, Italy, United Kingdom]. Results: 400 patients with 
diabetes [120 T1D; 280 T2D] completed the survey. Mean age (SD) was 54.5 (12.2) years 
[T1D: 50.3 (13.0); T2D: 56.3 (11.4)]. Average BMI was 29.9 (7.2) kg/m2 [T1D: 26.9 (4.9); 
T2D: 31.3 (7.7)]. Average time since diabetes diagnosis was 16.1 (11.7) years [T1D: 23.4 
(14.2); T2D: 13.0 (8.8)]. Total average MTI units taken per day (self-reported number 
of units taken at breakfast, lunch and dinner combined) was 54.8 (34.1) units [T1D: 
41.1 (21.9); T2D: 60.6 (36.7)]. 255 patients [63.8%] reported wasting no insulin, whereas 
145 patients [36.3%] reported wasting some insulin. Overall, patients reported dis-
carding 2.0 [95% CI 1.4–2.5] pens/cartridges per month on average that still had 
insulin remaining. Patients who reported wasting some insulin discarded on average 
8.6 [95% CI 7.2–10.0] units of MTI per pen/cartridge. cOnclusiOns: One third of 
patients taking > 20 units/day MTI reported discarding at least one 100 units/mL pen/
cartridge with insulin remaining. These results suggest there may be an opportunity 
to reduce insulin wastage with new higher strength MTI formulations that provide 
more total units per pen and fewer pen/cartridge transitions.
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Objectives: To investigate the frequency of hypoglycaemic episodes and its effect 
on diabetes management, healthcare resource use, economic burden and time loss 
(including time loss from work and daily life) for insulin-treated diabetes patients in 
urban China. MethOds: A questionnaire was used to collect data from 7 third-grade 
class-A hospitals in Beijing, Nanjing, Chengdu, Kunming and Ha’erbin in China from 
July to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included. Hypoglycaemia episodes were categorized as mild (symptoms could 
be self-disappeared), moderate (symptoms could not be self-disappeared), severe 
(coma happen, usually require medical assistance) and nocturnal (occur during 
sleep, including mild, moderate and severe) hypoglycaemia. Descriptive Statistic 
analysis was applied to the data. Results: More than half (56.7%) of 602 enrolled 
patients reported experiencing hypoglycaemia. 34.7%, 3.3% and 3.5% patients 
reported mild, moderate and nocturnal hypoglycaemia during the preceding month, 
with a total of 593, 84.5 and 45.5 episodes, respectively. 9 patients reported 12 severe 
hypoglycaemia episodes during the preceding year. Among patients experiencing 
hypoglycaemia, 15.5% reported anxiety of anti-diabetes drugs, 16.1% reported 
treatment regimens modification by themselves and 12.6% by their doctors, 19.9% 
reported extra self-monitoring of blood glucose of 3.14 times/week, 11.7% reported 
time loss by an average of 2 days/event, and 9.4% reported time loss for family 
members by an average of 1.89 days/event. Of the patients experiencing severe 
hypoglycaemia, 28.6% required emergency visit and 14.3% required hospitalization. 
Of patients experiencing nocturnal hypoglycaemia, 5.3% required hospitalization. 
Patients experiencing hypoglycaemia reported an average of hypoglycaemia-related 
cost of 44.06CNY/month. Nevertheless, for those who required medical assistance, 
the medical cost was 1216.53 CNY/event. cOnclusiOns: Hypoglycaemia was com-
mon in diabetes patients treated with insulin. Hypoglycaemia had negative impact 
on diabetes management and was associated with increasing healthcare utilization, 
economic burden and time loss for patients and family.
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Objectives: An adequate disease-related knowledge is important in treatment 
and management of ailments. Within this context, patients are needed to have 
for a better control of diabetes. cOnclusiOns: The responses of patients with 
both types of diabetes clearly show the need for new management approaches 
to alleviate the burden associated with the disease addressing the specific unmet 
needs of diabetic patients.
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Objectives: To use a discrete choice experiment (DCE) to evaluate preferences for 
the actual treatment features and overall profiles of two injectable glucagon-like 
peptide-1 (GLP-1) receptor agonists (dulaglutide and liraglutide) among patients 
with type 2 diabetes (T2DM) in the United Kingdom (UK). MethOds: In-person 
interviews were conducted in the UK to administer a DCE to patients with self-
reported T2DM, naïve to treatment with injectable medications. The DCE examined 
6 attributes of T2DM treatment each described by 2 levels: ‘dosing frequency,’ ‘HbA1c 
change,’ ‘weight change,’ ‘type of delivery system,’ ‘frequency of nausea,’ and ‘fre-
quency of hypoglycemia.’ Part-worth utilities were estimated using random effects 
logit models and used to calculate relative importance values for each attribute. A 
Chi-square test was used to determine differences in preferences for dulaglutide vs. 
liraglutide profiles. Results: A total of 243 participants [mean age: 60.5 (SD 10.9) 
years; 76.1% male; mean BMI: 29.8 (SD 5.4) kg/m2] completed the study. Relative 
importance values for the attributes in rank order were: ‘dosing frequency’ (41.6%), 
‘type of delivery system’ (35.5%), ‘frequency of nausea’ (10.4%), ‘weight change’ 
(5.9%), ‘HbA1c change’ (3.6%), and ‘frequency of hypoglycemia’ (3.0%). Significantly 
more participants preferred the dulaglutide profile (83.1%) compared to the liraglu-
tide profile (16.9%; p< 0.0001). cOnclusiOns: This study elicited patients’ prefer-
ences for attributes and levels representing the actual characteristics of two specific 
GLP-1 medications. In this context, dosing frequency and type of delivery system 
were most important, accounting for over 75% of the relative importance. While 
previous studies have identified efficacy as highly important in T2DM medication 
decisions, this study suggests that when differences in efficacy between medica-
tions are small, other treatment features (e.g., dosing frequency and delivery system) 
are of much greater importance to patients.
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Objectives: Understanding the preferences for attributes of T2DM treatments 
among patients in Spain. MethOds: Patients in Spain (self-reported physician 
diagnosis of T2DM, taking a prescription T2DM medication for > 2 years) com-
pleted an online discrete-choice experiment (DCE) survey (funded by GSK) to elicit 
preferences for T2DM treatment attributes. Respondents chose between pairs 
of hypothetical T2DM treatments defined by seven attributes: chance of reach-
ing target HbA1c, reduction in risk of serious heart attack or stroke, frequency 
of hypoglycemia, risk of gastrointestinal (GI) problems, weight change, mode of 
administration, and dosing frequency. Random-parameters logit (RPL) was used 
to analyze the data. Minimum acceptable benefit (MAB) was calculated with RPL 
coefficients and measures the percentage point (pp) increase in the probability of 
reaching target HbA1c that respondents require in order to accept worse levels of 
other attributes. Results: 401 patients responded (mean age 51, 77% male, 33% 
diagnosed more than 7 years ago). The DCE respondents preferred pills to injections 
and once-weekly dosing over other schedules. The highest MAB levels were: moving 
from pill to injection (MAB= 59pp), moving from once-weekly dosing frequency to 
more than twice a day (MAB= 40pp), moving from no risk of GI problems to 30% risk 
of GI problems (MAB= 37pp), moving from no hypos to more than 2 hypos per month 
(MAB= 37pp), and moving from a 2-kg weight loss to a 2-kg weight gain (MAB= 35pp). 
Respondents using injectables were indifferent between pills and injections, while 
respondents not using injectables had a strong preference for pills over injections 
(P = 0.00). cOnclusiOns: Respondents were willing to trade-off efficacy for an 
improvement in mode of administration (from injection to pills) and improved side 
effects . Given the variety of T2DM medications available, the results suggest that 
careful discussion about patient preferences could help improve patient satisfac-
tion with T2DM drugs.
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Objectives: This analysis of data from the DUAL V clinical trial compared health 
utility scores of IDegLira, a fixed-ratio combination of insulin degludec and liraglu-
tide, with insulin glargine (IGlar) in patients with type 2 diabetes (T2D). MethOds: 
Health status data were collected using the Short-Form 36 v2 (SF-36) questionnaire 
during a 26-week, multinational, multi-centre, open-label, parallel, randomised, 
treat-to-target trial comparing IDegLira (n= 278) with IGlar (n= 279) (either treat-
ment given once daily in addition to metformin) in patients with T2D, inadequately 
controlled on IGlar (20–50 units daily) and metformin (Buse et al. Diabetes 2015; 64 
(Suppl. 1):A43–A44; abstract 166-OR). In this post hoc analysis, SF-36 scores were 
mapped to the EuroQol-5D (EQ-5D) health utility scale using a validated algorithm 
(Model 3; Rowen et al. Health Qual Life Outcomes 2009;7:27). EQ-5D scores at end 
of trial (EOT) were analysed using an ANCOVA model with treatment and region 
